These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35362180)

  • 1. No apparent pharmacokinetic interactions were found between henagliflozin: A novel sodium-glucose co-transporter 2 inhibitor and glimepiride in healthy Chinese male subjects.
    Que L; Huang K; Xiang X; Ding Y; Chu N; He Q
    J Clin Pharm Ther; 2022 Aug; 47(8):1225-1231. PubMed ID: 35362180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and Pharmacodynamic Interactions Between Henagliflozin, a Novel Selective SGLT-2 Inhibitor, and Warfarin in Healthy Chinese Subjects.
    He X; Liu G; Chen X; Wang Y; Liu R; Wang C; Huang Y; Shen J; Jia Y
    Clin Ther; 2023 Jul; 45(7):655-661. PubMed ID: 37451912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of drug-drug interaction between henagliflozin, a novel sodium-glucose co-transporter 2 inhibitor, and metformin in healthy Chinese males.
    Wang L; Wu C; Shen L; Liu H; Chen Y; Liu F; Wang Y; Yang J
    Xenobiotica; 2016 Aug; 46(8):703-8. PubMed ID: 26608671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Henagliflozin, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter 2, in Healthy Subjects Following Single- and Multiple-dose Administration.
    Zhang YF; Liu YM; Yu C; Wang YT; Zhan Y; Liu HY; Zou JJ; Jia JY; Chen Q; Zhong DF
    Clin Ther; 2021 Feb; 43(2):396-409. PubMed ID: 33454124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Drug-Drug Interaction Between Henagliflozin and Hydrochlorothiazide in Healthy Chinese Volunteers.
    Chen Q; Yu C; Wu Q; Song R; Liu Y; Feng S; Yu C; Jia J
    Drug Des Devel Ther; 2024; 18():1855-1864. PubMed ID: 38828023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects.
    Yoo H; Kim Y; Jang IJ; Yu KS; Lee S
    Drug Des Devel Ther; 2020; 14():5179-5187. PubMed ID: 33262578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Food on the Pharmacokinetic Properties and Mass Balance of Henagliflozin in Healthy Male Volunteers.
    Chen ZD; Chen Q; Zhu YT; Zhang YF; Zhan Y; Chen XF; Liang X; Jia JY; Yu C; Liu HY; Zou JJ; Liu YM; Zhong DF
    Clin Ther; 2021 Sep; 43(9):e264-e273. PubMed ID: 34366153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Pharmacodynamics of Henagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus.
    Yong X; Wen A; Liu X; Liu H; Liu YP; Li N; Hu T; Chen Y; Wang M; Wang L; Dai X; Huang J; Li J; Shen H
    Clin Drug Investig; 2016 Mar; 36(3):195-202. PubMed ID: 26692004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Pharmacokinetic Interactions Between the New SGLT2 Inhibitor SHR3824 and Valsartan in Healthy Chinese Volunteers.
    Huang Y; Liu R; Wang Y; Liu G; Wang C; Chen X; Jia Y; Shen J
    Clin Ther; 2022 Jul; 44(7):945-956. PubMed ID: 35778161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor.
    Fediuk DJ; Nucci G; Dawra VK; Cutler DL; Amin NB; Terra SG; Boyd RA; Krishna R; Sahasrabudhe V
    Clin Pharmacokinet; 2020 Aug; 59(8):949-965. PubMed ID: 32337660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No Relevant Pharmacokinetic Drug-Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects.
    Kim YK; Hwang JG; Park MK
    Drug Des Devel Ther; 2021; 15():1725-1734. PubMed ID: 33953542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects.
    Dawra VK; Cutler DL; Zhou S; Krishna R; Shi H; Liang Y; Alvey C; Hickman A; Saur D; Terra SG; Sahasrabudhe V
    Clin Pharmacol Drug Dev; 2019 Apr; 8(3):314-325. PubMed ID: 29786959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
    Kasichayanula S; Liu X; Shyu WC; Zhang W; Pfister M; Griffen SC; Li T; LaCreta FP; Boulton DW
    Diabetes Obes Metab; 2011 Jan; 13(1):47-54. PubMed ID: 21114603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects.
    Dawra VK; Sahasrabudhe V; Liang Y; Matschke K; Shi H; Hickman A; Saur D; Terra SG; Cutler DL
    Clin Ther; 2018 Sep; 40(9):1538-1547. PubMed ID: 30170758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the
    Kim CO; Oh ES; Kim H; Park MS
    Drug Des Devel Ther; 2017; 11():503-512. PubMed ID: 28260863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects.
    Li Y; Mu Y; Shi H; Liang Y; Liu Z; Matschke K; Hickman A; Krishna R; Sahasrabudhe V
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):97-106. PubMed ID: 30934166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment.
    Sahasrabudhe V; Terra SG; Hickman A; Saur D; Raje S; Shi H; Matschke K; Zhou S; Cutler DL
    Clin Ther; 2018 Oct; 40(10):1701-1710. PubMed ID: 30224193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
.
    Dawra VK; Liang Y; Shi H; Bass A; Hickman A; Terra SG; Zhou S; Cutler D; Sahasrabudhe V
    Int J Clin Pharmacol Ther; 2019 Apr; 57(4):207-216. PubMed ID: 30802200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Food and Multiple-dose Administration on the Pharmacokinetic Properties of HR20033, a Sustained-release Formulation of Henagliflozin and Metformin for the Treatment of Diabetes, in Healthy Chinese Volunteers.
    Liu Y; Huyan X; Zhang Q; Qing H; Zhang Q; Wang X; Li Y; Liu Z; Hu W
    Clin Pharmacol Drug Dev; 2023 Apr; 12(4):376-384. PubMed ID: 36408821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
    Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.